We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Medical

Imagen

Status: Active

Jun 16th 2020 - Jul 17th 2020

Imagen is a company that has developed an automated, sophisticated algorithmic technique, PredictRx, to find the right treatment for any cancer type. Imagen collects the cancer samples from a patient, grows it in its specialised growth medium, and then subjects the medium to an automated fluorescence microscopy screening to measure drug responses on live tumour cells. The company's AI-powered biobank of over 150,000 drug responses then gives the best possible cancer treatment options, allowing the company to expand in the pharmaceutical sector by satisfying its unmet demand for patient-derived cancer models. Imgen requires investment to scale its infrastructure to create the world's leading 'Biobank' of clinically relevant patient-derived cancer models whilst building the most comprehensive big data set available in cancer research.

read more read less

Imagen Rating Review

Pitch rating powered by CROWDRATING

Rated on 22/06/2020

Pitch Rated

79%

overall

Management

90%

Product

76%

Investment

72%

Log in to view amount pledged

    Log in to view target

    £10,621,289
    pre-money valuation

    5.35%
    equity available

    668
    investors

    £1,552
    pledge per investor

    06373341
    company number

    Liquidation
    company status

    17/09/2007
    incorporated 17 years

    £6.33
    share price

    Previous Funding rounds
    15 Apr 24 Crowdcube £1,036,436 / 173% 79.33%
    Officers

What the ratings mean

  • 49% and under
    We suggest potential investors carry out further study of their own
    50-64%
    Room for improvement
    65-79%
    Worth considering
    80%+
    Gold rating, our highest rating

RISK WARNING - The ratings are based on the information provided in the fund raiser’s pitch deck, business plans and financial forecasts which have appeared on a FCA regulated crowdfunding site. Where possible we validate the business plan to public sources such as LinkedIn, Companies House, Credit Agencies and internet searches. We cannot guarantee the information is correct. The ratings report takes no account of the investors/ individual circumstances. Do your own due diligence and get professional advice before investing. Your capital is at risk when investing in private companies.

Login to view the full report

Management 90%

Skills 91%
Imagen has an experienced senior management team with nine full-time team members. The CEO of the company is a successful business leader and passionate about delivering value to patients, clients, and shareholders. He is skilled in biotechnology, business strategy, pharmaceutical sales, and oncology. The Chief Scientific Officer/Co-Founder has expertise in stem cells, translational research, cancer research, 3D cellular models, signal transduction, and toxicology. The business is also overseen by the Director of Business Development who is an expert in building the brand with his skills in sales management, biotechnology, business planning, team building, and new business development. It was noted that The company has outsourced finance through Alantra Corporate Finance LLP.

0 comments

Log in to comment


Funding progress

Log in to view funding progress.


Log in to view amount pledged

    Log in to view target

    £10,621,289
    pre-money valuation

    5.35%
    equity available

    668
    investors

    £1,552
    pledge per investor

    06373341
    company number

    Liquidation
    company status

    17/09/2007
    incorporated 17 years

    £6.33
    share price

    Previous Funding rounds
    16 Apr 24 Crowdcube £1,036,436 / 173% 79.33%
    Officers
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph